Showing results (131-140 of 174) with videos related to

Sort By:
Pageof 18
Journal of Cellular Physiology|October 17, 2022
The JMJD6/HURP axis promotes cell migration via NF-κB-dependent centrosome repositioning and Cdc42-mediated Golgi repositioningYun-Ru Jaoying Huang, Shao-Chih Chiu, Jeng-Sen Tseng, et al.
JCO Global Oncology|September 30, 2024
Registry of Genetic Alterations of Taiwan Non-Small Cell Lung Cancer by Comprehensive Next-Generation Sequencing: A Real-World Cohort Study-Taiwan Cooperative Oncology Group T1521Bin-Chi Liao, Nai-Jung Chiang, Gee-Chen Chang, et al.
Plos One|September 13, 2014
Impact of EGFR mutation detection methods on the efficacy of erlotinib in patients with advanced EGFR-wild type lung adenocarcinomaJeng-Sen Tseng, Chih-Liang Wang, Ming-Shyan Huang, et al.
The Journal of Antimicrobial Chemotherapy|February 6, 2024
Efficacy of cefoperazone/sulbactam for ESBL-producing Escherichia coli and Klebsiella pneumoniae bacteraemia and the factors associated with poor outcomesRou-Zhen Chen, Po-Liang Lu, Tsung-Ying Yang, et al.
Lung Cancer (Amsterdam, Netherlands)|February 19, 2017
Predictive factors for EGFR-tyrosine kinase inhibitor retreatment in patients with EGFR-mutated non-small-cell lung cancer - A multicenter retrospective SEQUENCE studyGee-Chen Chang, Chien-Hua Tseng, Kuo-Hsuan Hsu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 6, 2006
Identification of alpha-enolase as an autoantigen in lung cancer: its overexpression is associated with clinical outcomesGee-Chen Chang, Ko-Jiunn Liu, Chia-Ling Hsieh, et al.
Oncotarget|January 30, 2016
EGFR-activating mutations, DNA copy number abundance of ErbB family, and prognosis in lung adenocarcinomaHsuan-Yu Chen, Chia-Hsin Liu, Ya-Hsuan Chang, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 22, 2012
Aurora B kinase phosphorylates and instigates degradation of p53Chris P Gully, Guermarie Velazquez-Torres, Ji-Hyun Shin, et al.
Future Oncology (London, England)|December 18, 2025
Real-world treatment patterns and subsequent treatment effectiveness following frontline brigatinib in the ALTA-1L trialMyung-Ju Ahn, Angelo Delmonte, Sharmistha Ghosh, et al.
Molecular Cancer Therapeutics|May 13, 2026
BLU-451, a CNS-Active, Potent, and Selective Small-Molecule Inhibitor Against Uncommon EGFR MutationsYves A Millet, Alexander I Spira, Christina S Baik, et al.
Pageof 18